Skip to main content
Top
Published in: Pituitary 2/2019

01-04-2019 | Prolactinoma

Filamin A and DRD2 expression in corticotrophinomas

Authors: Thais Sickler, Ericka Barbosa Trarbach, Fernando Pereira Frassetto, Juliano Bertollo Dettoni, Venâncio Avancini Ferreira Alves, Maria Candida Barisson Villares Fragoso, Marcio Carlos Machado, Ellison Fernando Cardoso, Marcello Delano Bronstein, Andrea Glezer

Published in: Pituitary | Issue 2/2019

Login to get access

Abstract

Purpose

Filamin A (FLNA) expression is related to dopamine receptor type 2 (DRD2) expression in prolactinomas. Nevertheless, in corticotrophinomas, there are few studies about DRD2 expression and no data on FLNA. Therefore, we evaluated FLNA and DRD2 expression in corticotrophinomas and their association with tumor characteristics.

Methods

DRD2 and FLNA expression by immunohistochemistry, using H-score, based on the percentage of positive cells in a continuous scale of 0–300, were evaluated in 23 corticotrophinomas samples from patients submitted to neurosurgery. In six patients, treatment with cabergoline was indicated after non curative surgery.

Results

Twenty-two patients were female and one male. Regarding tumor size, 10 were micro and 12 were macroadenomas. DRD2 expression was found in 89% of cases and did not correlate with FLNA expression. Moreover, the response to cabergoline, observed in 33% of the cases, did not correlate with DRD2 nor FLNA expression. FLNA expression was not associated with clinical and tumor characteristics, except for sphenoid sinus invasion.

Conclusions

In our cohort of corticotrophinomas, DRD2 expression was not associated with FLNA expression nor to the response to CAB. Nonetheless, FLNA expression could be related to tumor invasiveness.
Literature
1.
go back to reference Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135CrossRefPubMed Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G et al (2013) A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol 126(1):123–135CrossRefPubMed
2.
go back to reference Lindholm J, Juul S, Jorgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U et al (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed Lindholm J, Juul S, Jorgensen JOL, Astrup J, Bjerre P, Feldt-Rasmussen U et al (2001) Incidence and late prognosis of Cushing’s syndrome: a population-based study. J Clin Endocrinol Metab 86(1):117–123PubMed
3.
go back to reference Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin N Am 34(2):327–339CrossRef Pivonello R, Faggiano A, Lombardi G, Colao A (2005) The metabolic syndrome and cardiovascular risk in Cushing’s syndrome. Endocrinol Metab Clin N Am 34(2):327–339CrossRef
4.
go back to reference Solak M, Kraljevic I, Dusek T, Melada A, Kavanagh MM, Peterkovic V et al (2016) Management of Cushing’s disease: a single-center experience. Endocrine 51(3):517–523CrossRefPubMed Solak M, Kraljevic I, Dusek T, Melada A, Kavanagh MM, Peterkovic V et al (2016) Management of Cushing’s disease: a single-center experience. Endocrine 51(3):517–523CrossRefPubMed
5.
go back to reference Machado MC, Alcantara AEE, Pereira ACL, Cescato VAS, Musolino NRC, de Mendonca BB et al (2016) Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas. J Endocrinol Investig 39(12):1401–1409CrossRef Machado MC, Alcantara AEE, Pereira ACL, Cescato VAS, Musolino NRC, de Mendonca BB et al (2016) Negative correlation between tumour size and cortisol/ACTH ratios in patients with Cushing’s disease harbouring microadenomas or macroadenomas. J Endocrinol Investig 39(12):1401–1409CrossRef
6.
go back to reference Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO et al (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral Nieman LK, Biller BMK, Findling JW, Murad MH, Newell-Price J, Savage MO et al (2015) Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 100(8):2807–2831CrossRefPubMedPubMedCentral
7.
go back to reference Cuevas-Ramos D, Fleseriu M (2016) Medical treatment of Cushing’s disease. Minerva Endocrinol 41(3):324–340PubMed Cuevas-Ramos D, Fleseriu M (2016) Medical treatment of Cushing’s disease. Minerva Endocrinol 41(3):324–340PubMed
8.
go back to reference Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing’s syndrome. Endocrinol Metab Clin N Am 37(1):135–149CrossRef Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing’s syndrome. Endocrinol Metab Clin N Am 37(1):135–149CrossRef
9.
go back to reference Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro MLD, Arvigo M et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452–2462CrossRefPubMed Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro MLD, Arvigo M et al (2004) Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89(5):2452–2462CrossRefPubMed
10.
go back to reference Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G et al (2009) The medical treatment of cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230CrossRefPubMed Pivonello R, De Martino MC, Cappabianca P, De Leo M, Faggiano A, Lombardi G et al (2009) The medical treatment of cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94(1):223–230CrossRefPubMed
11.
go back to reference Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163(5):709–716CrossRefPubMed Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A (2010) Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 163(5):709–716CrossRefPubMed
12.
go back to reference Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T et al (2010) Efficacy of cabergoline in uncured (persistent or recurrent) cushing disease after pituitary surgical treatment with or without radiotherapy. Endocrine Pract 16(6):968–976CrossRef Lila AR, Gopal RA, Acharya SV, George J, Sarathi V, Bandgar T et al (2010) Efficacy of cabergoline in uncured (persistent or recurrent) cushing disease after pituitary surgical treatment with or without radiotherapy. Endocrine Pract 16(6):968–976CrossRef
13.
go back to reference Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Silva LME et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129CrossRefPubMed Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Silva LME et al (2010) Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 13(2):123–129CrossRefPubMed
14.
go back to reference Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O et al (2017) Cabergoline for Cushing’s disease: a large retrospective multicenter study. Eur J Endocrinol 176(3):305–314CrossRefPubMed Ferriere A, Cortet C, Chanson P, Delemer B, Caron P, Chabre O et al (2017) Cabergoline for Cushing’s disease: a large retrospective multicenter study. Eur J Endocrinol 176(3):305–314CrossRefPubMed
15.
go back to reference Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S et al (2012) Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab 97(3):967–977CrossRefPubMed Peverelli E, Mantovani G, Vitali E, Elli FM, Olgiati L, Ferrero S et al (2012) Filamin-A is essential for dopamine D2 receptor expression and signaling in tumorous lactotrophs. J Clin Endocrinol Metab 97(3):967–977CrossRefPubMed
16.
go back to reference Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiaghi V, Locatelli M et al (2014) Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology 155(8):2932–2941CrossRefPubMed Peverelli E, Giardino E, Treppiedi D, Vitali E, Cambiaghi V, Locatelli M et al (2014) Filamin A (FLNA) plays an essential role in somatostatin receptor 2 (SST2) signaling and stabilization after agonist stimulation in human and rat somatotroph tumor cells. Endocrinology 155(8):2932–2941CrossRefPubMed
17.
go back to reference Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary-adenomas with invasion of the cavernous sinus space—a magnetic-resonance-imaging classification compared with surgical findings. Neurosurgery 33(4):610–618PubMed Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary-adenomas with invasion of the cavernous sinus space—a magnetic-resonance-imaging classification compared with surgical findings. Neurosurgery 33(4):610–618PubMed
18.
go back to reference Hardy J, Vezina JL (1976) Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 15:261–273PubMed Hardy J, Vezina JL (1976) Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 15:261–273PubMed
19.
go back to reference Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M et al (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7):945–954CrossRefPubMedPubMedCentral Jordan RC, Lingen MW, Perez-Ordonez B, He X, Pickard R, Koluder M et al (2012) Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 36(7):945–954CrossRefPubMedPubMedCentral
20.
go back to reference Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am 37(1):67–99CrossRef Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin N Am 37(1):67–99CrossRef
21.
go back to reference Shao QQ, Zhang TP, Zhao WJ, Liu ZW, You L, Zhou L et al (2016) Filamin A: insights into its exact role in cancers. Pathol Oncol Res 22(2):245–252CrossRefPubMed Shao QQ, Zhang TP, Zhao WJ, Liu ZW, You L, Zhou L et al (2016) Filamin A: insights into its exact role in cancers. Pathol Oncol Res 22(2):245–252CrossRefPubMed
22.
go back to reference Bachmann AS, Howard JP, Vogel CW (2006) Actin-binding protein filamin A is displayed on the surface of human neuroblastoma cells. Cancer Sci 97(12):1359–1365CrossRefPubMed Bachmann AS, Howard JP, Vogel CW (2006) Actin-binding protein filamin A is displayed on the surface of human neuroblastoma cells. Cancer Sci 97(12):1359–1365CrossRefPubMed
23.
go back to reference Coughlin MF, Puig-de-Morales M, Bursac P, Mellema M, Millet E, Fredberg JJ (2006) Filamin-A and rheological properties of cultured melanoma cells. Biophys J 90(6):2199–2205CrossRefPubMed Coughlin MF, Puig-de-Morales M, Bursac P, Mellema M, Millet E, Fredberg JJ (2006) Filamin-A and rheological properties of cultured melanoma cells. Biophys J 90(6):2199–2205CrossRefPubMed
24.
go back to reference Zhu TN, He HJ, Kole S, D’Souza T, Agarwal R, Morin PJ et al (2007) Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J Biol Chem 282(20):14816–14826CrossRefPubMed Zhu TN, He HJ, Kole S, D’Souza T, Agarwal R, Morin PJ et al (2007) Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J Biol Chem 282(20):14816–14826CrossRefPubMed
25.
go back to reference Jiang X, Yue JY, Lu HM, Campbell N, Yang QF, Lan SJ et al (2013) Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci 9(1):67–77CrossRefPubMed Jiang X, Yue JY, Lu HM, Campbell N, Yang QF, Lan SJ et al (2013) Inhibition of filamin-A reduces cancer metastatic potential. Int J Biol Sci 9(1):67–77CrossRefPubMed
26.
go back to reference Sun GG, Sheng SH, Jing SW, Hu WN (2014) An antiproliferative gene FLNA regulates migration and invasion of gastric carcinoma cell in vitro and its clinical significance. Tumor Biol 35(3):2641–2648CrossRef Sun GG, Sheng SH, Jing SW, Hu WN (2014) An antiproliferative gene FLNA regulates migration and invasion of gastric carcinoma cell in vitro and its clinical significance. Tumor Biol 35(3):2641–2648CrossRef
27.
go back to reference Savoy RM, Ghosh PM (2013) The dual role of filamin A in cancer: can’t live with (too much of) it, can’t live without it. Endocr Relat Cancer 20(6):R341–R356CrossRefPubMedPubMedCentral Savoy RM, Ghosh PM (2013) The dual role of filamin A in cancer: can’t live with (too much of) it, can’t live without it. Endocr Relat Cancer 20(6):R341–R356CrossRefPubMedPubMedCentral
Metadata
Title
Filamin A and DRD2 expression in corticotrophinomas
Authors
Thais Sickler
Ericka Barbosa Trarbach
Fernando Pereira Frassetto
Juliano Bertollo Dettoni
Venâncio Avancini Ferreira Alves
Maria Candida Barisson Villares Fragoso
Marcio Carlos Machado
Ellison Fernando Cardoso
Marcello Delano Bronstein
Andrea Glezer
Publication date
01-04-2019
Publisher
Springer US
Published in
Pituitary / Issue 2/2019
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-00947-x

Other articles of this Issue 2/2019

Pituitary 2/2019 Go to the issue